In major STEP trials, Wegovy led to about 15% weight loss over 68 weeks. Contrave (called Mysimba in the UK) generally achieves around 6–9% across pivotal studies. This means semaglutide tends to provide greater weight reduction than naltrexone/bupropion combinations. Two very different approaches Although both Wegovy and Contrave are prescribed for weight management, they work in completely different ways. Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces ap

Yes, Wegovy and metformin are often used together in people with type 2 diabetes, and no special dose adjustment is typically required. They work differently: Wegovy (a GLP-1 receptor agonist) reduces appetite, slows stomach emptying, and boosts insulin release, while metformin mainly reduces glucose production in the liver and improves insulin sensitivity. Why these medicines are combined Doctors frequently prescribe Wegovy (semaglutide) alongside metformin, particularly in

In a head-to-head trial published in The New England Journal of Medicine , people taking Wegovy lost on average about 15.8% of their body weight over 68 weeks compared with 6.4% for those on Saxenda (liraglutide). This makes Wegovy the more effective of the two for weight loss in most cases. Two GLP-1 medicines, one key difference Both Wegovy and Saxenda belong to the same class of medicines, known as GLP-1 receptor agonists. They work by mimicking a natural hormone that redu

Wegovy contains semaglutide at a higher dose and is licensed for weight management, while Trulicity (dulaglutide) is prescribed for type 2 diabetes. Weight changes with dulaglutide are usually modest compared with the significant reductions seen in trials of semaglutide for obesity. Two GLP-1 medicines, two purposes Both Wegovy and Trulicity belong to the same broad group of medicines known as GLP-1 receptor agonists. They mimic a natural hormone in the body that helps reduce

For weight management, Wegovy (semaglutide 2.4 mg weekly) is the licensed option and generally achieves greater weight loss than the...

Choosing between Wegovy and Mounjaro comes down to what you’re aiming for (weight, blood sugar, side-effect profile) and what’s available to you. Many people see strong results with both; tirzepatide can yield greater reductions for some, while semaglutide has a longer real-world track record. Why these two drugs stand out Wegovy and Mounjaro are often compared because they’re part of the same family of treatments known as incretin-based medicines. Both act on hormones that h

Wegovy contains semaglutide, a GLP-1 receptor agonist used at higher weekly doses for weight management. It helps reduce appetite and supports lower energy intake alongside everyday habits like balanced eating and movement. What semaglutide actually is Semaglutide is a medicine that mimics GLP-1 (glucagon-like peptide-1), a natural hormone in the body. GLP-1 plays a key role in appetite and metabolism: it slows the emptying of the stomach, enhances the release of insulin when

Wegovy and Ozempic share the same active ingredient (semaglutide), but they’re licensed for different uses and doses — Wegovy for weight...

Many people report fewer intrusive food thoughts, less urgency around snacking, and improved control in situations that previously triggered overeating. That can ease emotional or stress-linked eating because the immediate pull of ultra-palatable foods is quieter. Wegovy isn’t a treatment for mental-health conditions, so ongoing support — sleep, stress tools, counselling if needed — remains important. If mood changes occur, tell your clinical team so they can review and suppo

Wegovy isn’t licensed in the UK to treat fatty liver or other conditions directly, but weight reduction can improve liver fat and broader...

Storage is straightforward: keep pens in the refrigerator in their original carton, and do not freeze. Protect from light and check the...

Wegovy acts directly on GLP-1 receptors; effects on ghrelin and leptin are indirect and vary between individuals. By strengthening...

Wegovy is a once-weekly subcutaneous injection given into the abdomen, thigh, or upper arm. Rotate sites each week and avoid areas that...

The duration is guided by your response, tolerability, and local commissioning policy. Services typically build in review points — for example, at six months and at later milestones — to check progress and decide on continuation. Some pathways set a maximum course length; others allow ongoing use if agreed benchmarks are met within specialist care. Your team will set expectations clearly at the start so you know how and when decisions will be made. Why duration is not the sam

There isn’t a one-off loading dose; instead there’s a gradual dose-escalation (titration) phase. You start low and step up in stages...

After stopping, many people regain some weight over time because appetite signals gradually return toward baseline. How much and how quickly varies, but the pattern is common across all weight-management approaches. Planning ahead helps: keep protein intake consistent, maintain activity that preserves strength, and agree a follow-up plan with your team (for example, a slower taper, maintenance strategies, or alternative support). If you stop because goals have been met, expec

Yes — both men and women can use Wegovy when they meet eligibility criteria. Because exposure in pregnancy isn’t recommended, women of child-bearing potential are advised to use effective contraception and to discuss stopping in advance if planning a pregnancy. If you become pregnant, contact your clinical team promptly to review treatment. Apart from pregnancy and breastfeeding considerations, the approach to dosing and monitoring is similar across genders. Equal access in e

In UK services, routine age use focuses on adults within specialist pathways. Use in people under 18 is specialist and not part of standard adult commissioning routes. If a young person is being considered for treatment, this would happen in paediatric services with multidisciplinary input and careful assessment of risks and benefits. Focus on adults in UK guidance In the UK, Wegovy is commissioned primarily for adults who meet strict eligibility criteria. NICE guidance and c

Energy levels often feel steadier as erratic snacking and large swings in intake settle down. Some people notice early fatigue during dose increases; this usually improves with better hydration, regular meals, and enough protein. If tiredness persists, your team can adjust the titration pace or check for other contributors such as low iron or not eating enough. What to expect in the first weeks Many people describe two parallel experiences at the start. On the one hand, appet

Wegovy was developed by Novo Nordisk as a higher-dose formulation of the GLP-1 receptor agonist semaglutide for chronic weight management, building on earlier experience with semaglutide for type 2 diabetes. Its evidence base comes from large, international STEP trials focused on weight and related health markers, with additional research exploring cardiovascular and kidney outcomes in selected groups. UK adoption is guided by national appraisals and commissioning policies; S